Prescription Lens Market Updates

Global Prescription Lens Market size was valued at USD 45.8 billion in 2023 and is poised to grow from USD 48.23 billion in 2024 to USD 72.9 billion by 2032, growing at a CAGR of 5.3% during the forecast period (2025-2032).

Major players are concentrating on developing multiple kinds of prescription glasses with various coating options. These market participants are also forming partnerships and alliances in order to broaden their brand reach and enhance their product offerings. For instance, Essilor launched a progressive web app version of the pre-existing Essilor Companion for all eye care professionals. This initiative aims to simplify the digital ecosystem for Essilor's industry partners, such as Eye Care Professionals (ECPs), while also providing a better in-store digital Essilor brand experience. 'Essilor International S.A. (France) ', 'Johnson & Johnson Vision Care, Inc. (US) ', 'Luxottica Group S.p.A. (Italy) ', 'Hoya Corporation (Japan) ', 'ZEISS International (Germany) ', 'CooperVision, Inc. (US) ', 'Marchon Eyewear, Inc. (US) ', 'Safilo Group S.p.A. (Italy) ', 'Fielmann AG (Germany) ', 'Carrington Opticians (UK) ', 'Bausch + Lomb (US) ', 'Transitions Optical, Inc. (US) ', 'The Vision Council (US) ', 'GrandVision N.V. (Netherlands) ', 'Rodenstock GmbH (Germany) ', 'Mitsui Chemicals, Inc. (Japan) ', 'Seiko Optical Products Co., Ltd. (Japan) ', 'VSP Global (US) ', 'Carl Zeiss Vision International (Germany) ', 'EyeQue Corporation (US)'

The rising prevalence of refractive error cases, primarily myopia and refractive error, is expected to drive prescription lens demand. Prescription lenses aid in the resolution of the eyes' incapability to project light onto the retina for improved vision. These lenses come in a variety of shapes and sizes and surface coatings and are preferred based on refractive order. Concave prescription optics are used to correct myopia, while convex prescription lenses are used to correct hyperopia. Conical prescription lenses are used to correct astigmatism.

ZEISS is a leading manufacturer of lenses that include BlueGuard Lenses, Sunglass Lenses, Single Vision Lenses, Digital Lenses, Progressive Lenses, and Drive Safe Lenses. ZEISS is developing BlueGuard Lenses, an advanced prescription lens based on ZEISS UVProtect Technology that blocks up to 40% of potentially harmful blue light in the wavelength range of 400 nm to 455 nm. During the forecast period, the development of such a technologically advanced prescription lens is expected to boost the market growth. Furthermore, beginning in 2022, ZEISS will set a new standard of care by including full UV protection in all clear ZEISS plastic lenses.

During the forecast period, Asia-Pacific is expected to have the largest market share. China, Japan, Singapore, and the Republic of Korea are significant contributors to the region's Prescription Lens market growth. These countries account for half of the world's myopia prevalence. The region's increasing incidence of refractive errors is raising the number of patients and, as a result, the requirement for prescription lenses for their treatment. Market participants in the region are forming strategic alliances to expand their prescription lens business. Hoya announced a partnership with Orbis International, a global organization that provides mentorship and training to local eye care professionals and inspires them to save sight in their communities.